Curated News
By: NewsRamp Editorial Staff
September 11, 2024

MAIA Biotechnology's THIO Shows Positive Interim Survival Benefits in Non-Small Cell Lung Cancer Study

Reddit Discuss on RedditDiscuss on LinkedIn LinkedInDiscuss on Substack SubstackDiscuss on Telegram TelegramView History of this news story on GitHub Github
Source News Release

TLDR

  • MAIA Biotechnology reports positive interim survival benefits in phase 2 study of THIO, a potential treatment for advanced non-small cell lung cancer.
  • THIO from MAIA targets and attacks telomeres, a key factor in helping cancer cells live and spread, inducing telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death.
  • MAIA's THIO could become a treatment option for people suffering from advanced NSCLC, potentially improving the survival rate and offering hope to cancer patients.
  • THIO's exceptional efficacy data from the phase 2 trial demonstrates favorable disease control, overall response rates, and median progression-free survival, advancing its clinical profile as a strong, safe, and highly effective alternative for cancer patients.

Impact - Why it Matters

This news matters as it highlights the promising results of THIO, a new therapy for advanced non-small cell lung cancer. If successful, it could provide a more effective treatment option for patients with NSCLC and potentially other forms of cancer, impacting the future of cancer care and the pharmaceutical industry.

Summary

MAIA Biotechnology Inc. (NYSE: MAIA), a clinical-stage biopharmaceutical company, reported positive interim survival benefits in a phase 2 study of THIO, its lead therapy to fight advanced non-small cell lung cancer (NSCLC). The company is evaluating THIO sequenced with Regeneron Pharmaceuticals Inc.'s immune checkpoint inhibitor (CPI) cemiplimab in patients with advanced NSCLC who failed two or more standard-of-care therapy regimens. THIO targets and attacks telomeres, which play a key role in helping cancer cells live and spread. The 12-month survival data corresponds to MAIA’s most recent data from THIO-101 demonstrating favorable disease control and overall response rates. If this treatment proves effective, MAIA plans to use THIO in treating other forms of cancer, such as hepatocellular carcinoma (HCC), small cell lung cancer (SCLC) and malignant gliomas.

Source Statement

This curated news summary relied on this press release disributed by News Direct. Read the source press release here, MAIA Biotechnology's THIO Shows Positive Interim Survival Benefits in Non-Small Cell Lung Cancer Study

blockchain registration record for the source press release.